Using targeted therapies to treat uterine serous carcinoma
Official title: Targeting uterine serous carcinoma with antibody-drug conjugates
Funded at University of Tx Md Anderson Can Ctr · NIH-11124339 · Data updated 2026-11-12
This study is looking at new treatments for uterine serous carcinoma, an aggressive type of cancer, by using special drugs that target the cancer cells, and it aims to find the best ways to make these treatments work even better for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $204,372 |
| NIH project number | 3P50CA281701-02S2 |
| Project ID | NIH-11124339 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with uterine serous carcinoma who may benefit from targeted cancer therapies.
✕Less likely to help
Patients with other types of cancer or those without uterine serous carcinoma may not receive any benefit from this research.
What this research studies
This research focuses on developing antibody-drug conjugates (ADCs) as a treatment for uterine serous carcinoma (USC), a type of aggressive cancer. The project aims to identify specific targets within USC tissues that can be effectively treated with these novel therapies. Researchers will analyze tissue samples to understand the expression of these targets and test the effectiveness of ADCs in laboratory models. By combining these therapies with other agents, they hope to enhance treatment outcomes for patients with USC.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with uterine serous carcinoma.
How similar studies have gone: Previous research has shown promising results with antibody-drug conjugates in treating various solid tumors, indicating potential success for this approach in USC.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Understanding how bladder cancer starts in Veterans exposed to carcinogens and the role of PPAR-g in early bladder cancer
A research team is studying how bladder cancer begins and progresses in Veterans exposed to carcinogens, focusing on the PPAR-γ protein and early precancerous changes.
-
Adding PSMA PET/CT imaging to liver cancer care for veterans
This project tests a new PET imaging approach to help diagnose and guide treatment for liver cancer in veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.